



Pulmonary hypertension in an adolescent with end-stage-renal disease—a diagnostic challenge: Answers

Julien Hogan¹ · Rémi Salomon² · Saoussen Krid² · Damien Bonnet³ · Antoine Legendre³

Received: 12 February 2018 / Accepted: 13 February 2018
© IPNA 2018

Keywords Pulmonary hypertension · Vascular access · Hemodialysis · Arteriovenous fistula · Children

Answers

What is the cause of the pulmonary hypertension in this patient?

The initial hypothesis was that the heart failure was related to left ventricular (LV) diastolic dysfunction secondary to systemic thrombotic microangiopathy (TMA) and end-stage renal disease (ESRD). This is consistent with the echocardiographic findings showing dilated LV with a normal systolic function. Although LV diastolic dysfunction is associated with elevated pulmonary pressure, the results of the catheterization showed that, in our patient, pulmonary hypertension (PH) was related to a pulmonary overflow due to a massive arteriovenous left-to-right shunt at the femoral level as demonstrated by the abnormally high oxygen saturation found in the inferior vena cava. Of note, the last Doppler assessing the fistula blood flow performed in 2008 was already showing high blood flow of 2 L/min.

How should the pulmonary hypertension in this patient be treated?

The femoral arteriovenous (A-V) fistula was closed surgically. Subsequent echocardiography showed normalization of the

pulmonary pressure (32/10 mean 20 mmHg) and of the cardiac index (4 L/min/m²). Renal function also improved [estimated glomerular filtration rate (eGFR) increased from 27 to 38 ml/min/m²] by relief of the steal phenomenon through the fistulae. Of note, our patient did not present signs of steal phenomenon in the lower limbs.

Discussion

Patients with ESRD require regular cardiac follow-up since cardiovascular disease is the leading cause of death. Recent studies demonstrate that up to 92% of children with ESRD have cardiovascular risk factors and that their cardiac follow-up is underprovided [1]. Moreover, patients with ESRD have an increased prevalence of PH [2] that may be caused by various mechanisms (Group 5 of the Dana Point classification) [3].

The present case report illustrates the multifactorial aspects of PH in ESRD. Indeed, elevation of pulmonary pressure could have been related to left-heart diastolic dysfunction, to ESRD itself, or to pulmonary overflow. Fortunately, PH was fully reversible after closure of the shunt, as suggested by the right heart catheterization that showed pulmonary vascular resistance (PVRi) within the reversible range in patients with cardiac shunts [4]. To date, no case of PH caused by an A-V access has been described in children, but several cases have been reported in adult patients [5, 6]. Invasive hemodynamic testing was reassuring in our patient, but did not exclude pulmonary vascular disease. It is indeed still debated whether or not increased pulmonary blood flow secondary to an A-V access can lead to pulmonary vascular disease in patients undergoing hemodialysis. Several conditions inducing an increase in neonatal and fetal pulmonary blood flow are known to produce pulmonary vessel remodeling [7–11] and PH. Our case stresses the difference between the terms “pulmonary vascular disease” and “pulmonary arterial hypertension”—they are not interchangeable. In

This refers to the article that can be found at <https://doi.org/10.1007/s00467-018-3931-5>.

✉ Julien Hogan
julien.hogan@hotmail.fr

¹ Pediatric Nephrology Department, Robert Debré University Hospital, APHP, 48 bld Sérurier, 75019 France, France

² Pediatric Nephrology Department, Necker University Hospital, APHP, Paris, France

³ Pediatric Cardiology Department, Necker University Hospital, APHP, Paris, France

congenital cardiac left-to-right shunts, patients with moderate to large defects can have pulmonary arterial hypertension, but not necessarily an irreversible pulmonary vascular disease (i.e., a permanently and extensively remodeled pulmonary vascular bed). In cases where pulmonary artery pressure and blood flow are high, but PVRi is within normal limits or slightly elevated, the patient can be considered a suitable candidate for closure of the shunt. In this scenario, pulmonary vascular lesions are likely not to be extensive. Our patient remains at risk for unfavorable pulmonary vessel remodeling because of the other risk factors associated with ESRD [12]. Indeed, alteration of pulmonary vessel endothelial function, with an increase of serum Endothelin-1 levels and a decrease of NO levels, has been found in patients with ESRD and PH when compared to patients with ESRD but without PH [6]. It has also been suggested that the pathophysiology of the pulmonary vascular disease in ESRD involves a variety of factors besides arteriovenous (A-V) access, such as uremia or elevated parathyroid hormone [13].

PH can also be post-capillary in patients with ESRD as LV diastolic dysfunction is a common finding in patients undergoing chronic hemodialysis [14], regardless of the etiology of ESRD. The TMA that our patient developed after his first renal transplant may have caused direct myocardial damage as seen in hemolytic uremic syndrome [15–17], and this might have contributed to the post-capillary component of his PH.

Conclusion

This report emphasizes the need to regularly check the A-V fistula blood flow in children as recommended in adult guidelines (e.g., NF-K/DOQI) in order to diagnose excessive shunting. We also confirmed the complexity and the multifactorial etiologies of PH in children with ESRD. We suggest that, as in cardiac left-to-right shunts, right heart catheterization should be performed when an arteriovenous shunt is suspected as a possible contributor to increased pulmonary pressure in patients with ESRD.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

- Chavers BM, Solid CA, Sinaiko A, Daniels FX, Chen SC, Collins AJ, Frankenfield DL, Herzog CA (2011) Diagnosis of cardiac disease in pediatric end-stage renal disease. *Nephrol Dial Transplant* 26:1640–1645
- Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, Reisner SA (2003) Pulmonary hypertension in patients with end-stage renal disease. *Chest* 123:1577–1582
- Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG) (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J* 30:2493–2537
- Lopes AA, O'Leary PW (2009) Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. *Cardiol Young* 19:431–435
- Beigi AA, Sadeghi AM, Khosravi AR, Karami M, Masoudpour H (2009) Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. *J Vasc Access* 10:160–166
- Nakhoul F, Yigla M, Gilman R, Reisner SA, Abassi Z (2005) The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. *Nephrol Dial Transplant* 20:1686–1692
- Abman SH, Accurso FJ (1989) Acute effects of partial compression of ductus arteriosus on fetal pulmonary circulation. *Am J Phys* 257: H626–H634
- Chevreton L, Durand P, Alvarez H, Lambert V, Caeymax L, Rodesch G, Devictor D, Lasjaunias P (2002) Severe cardiac failure in newborns with VGAM. Prognosis significance of hemodynamic parameters in neonates presenting with severe heart failure owing to vein of Galen arteriovenous malformation. *Intensive Care Med* 28: 1126–1130
- Jouannic JM, Roussin R, Hislop AA, Lanone S, Martinovic J, Boczkowski J, Dumez Y, Dinh-Xuan AT (2003) Systemic arteriovenous fistula leads to pulmonary artery remodeling and abnormal vasoreactivity in the fetal lamb. *Am J Physiol Lung Cell Mol Physiol* 285:L701–L709
- Jouannic JM, Bonnet D, Hislop AA, Roussin R, Dinh-Xuan AT (2004) Noninvasive assessment of fetal pulmonary blood flow in experimental pulmonary hypertension in the fetal lamb. *Pediatr Res* 56:385–390
- Thatrimontrichai A, Chanvitan P, Janjindamai W, Dissaneevate S, Kritsaneepaiboon S, Hongsakul K (2012) Congenital hepatic arteriovenous malformation presenting with severe persistent pulmonary hypertension. *Indian J Pediatr* 79:673–675
- Unal A, Tasdemir K, Oymak S, Duran M, Kocyigit I, Oguz F, Tokgoz B, Sipahioglu MH, Utas C, Oymak O (2010) The long-term effects of arteriovenous fistula creation on the development of pulmonary hypertension in hemodialysis patients. *Hemodial Int* 14: 398–402
- Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O, Dinc G (2007) Pulmonary hypertension in patients with chronic renal failure. *Respiration* 74:503–510
- Goren A, Glaser J, Drukker A (1993) Diastolic function in children and adolescents on dialysis and after kidney transplantation: an echocardiographic assessment. *Pediatr Nephrol* 7:725–728
- Ohomoto A, Kohno M, Matsuyama R (1993) An autopsy case report of hemolytic uremic syndrome after allogeneic bone marrow transplantation. *Rinsho Ketsueki* 34:229–231
- Said T, Al-Otaibi T, Al-Wahaib S, Francis I, Nair MP, Halim MA, El-Sayed A, Nampoory MR (2010) Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. *Transplant Proc* 42:814–816
- Walker AM, Benson LN, Wilson GJ, Arbus GS (1997) Cardiomyopathy: a late complication of hemolytic uremic syndrome. *Pediatr Nephrol* 11:221–222